VIVIAN WANJOHI: Open Payments
NPI 1851039200 · NEW HAVEN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,221 in 52 payments from 27 companies in 2025. Trend: 2023 $1,315 · 2024 $2,670 · 2025 $1,221
Food & beverage: $1,083Education: $138
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $122 |
| Celgene Corporation | 4 | $110 |
| Incyte Corporation | 5 | $105 |
| SEAGEN INC. | 1 | $88 |
| ARRAY BIOPHARMA INC | 5 | $78 |
| PFIZER INC. | 5 | $76 |
| Janssen Biotech, Inc. | 2 | $67 |
| Rigel Pharmaceuticals, Inc. | 3 | $66 |
| JAZZ PHARMACEUTICALS INC. | 3 | $57 |
| Merck Sharp & Dohme LLC | 2 | $42 |
Products named: REBLOZYL, VENCLEXTA, LORBRENA, DARZALEX, TAVALISSE, JAKAFI, ZEPZELCA, MONJUVI.
Industry payments across CT — which companies pay providers there.
